Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Eftilagimod Alpha

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immutep Collaborates With Gw Cancer Center To Evaluate
    Immutep Collaborates With Gw Cancer Center To Evaluate

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153886/0/en/Immutep-Announces-Research-Collaboration-with-the-George-Washington-University-Cancer-Center-to-Evaluate-Neoadjuvant-Efti.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Immutep to Present Ph2 EFTISARC-NEO Efti Data in Sarcoma at CTOS
    Immutep to Present Ph2 EFTISARC-NEO Efti Data in Sarcoma at CTOS

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3146032/0/en/Immutep-Announces-Data-from-EFTISARC-NEO-Phase-II-Evaluating-Neoadjuvant-Efti-in-Soft-Tissue-Sarcoma-Accepted-for-Oral-Presentation-at-CTOS-2025.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Immutep Combo Hits Endpoint in Ph2 Sarcoma Study
    Immutep Combo Hits Endpoint in Ph2 Sarcoma Study

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088523/0/en/Immutep-s-Efti-with-Radiotherapy-KEYTRUDA-pembrolizumab-Meets-Primary-Endpoint-in-Phase-II-for-Soft-Tissue-Sarcoma.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share
    Immutep’s efti with PD-L1 achieves high response in lung cancer
    Immutep’s efti with PD-L1 achieves high response in lung cancer

    16 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/15/3082100/0/en/Immutep-s-Efti-with-KEYTRUDA-pembrolizumab-Chemotherapy-Achieves-High-Response-Rates-in-First-Line-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    16 May 2025
    Share Share
    Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design
    Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design

    22 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/22/2916491/0/en/Immutep-Announces-Successful-Meeting-with-FDA-on-Phase-III-Design-in-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    22 Jul 2024
    Share Share
    Immutep Reports Positive Results In First Line Head And Neck Cancer
    Immutep Reports Positive Results In First Line Head And Neck Cancer

    11 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/11/2912179/0/en/Immutep-Reports-Positive-Results-in-First-Line-Head-and-Neck-Squamous-Cell-Carcinoma-Patients-with-Negative-PD-L1-Expression.html

    GLOBENEWSWIRE
    11 Jul 2024
    Share Share